£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase …
Post
-
-
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal …
-
Aicuris reports positive Phase III pritelivir results for HSV patients
Aicuris has reported positive findings from its pivotal Phase III trial (PRIOH-I) assessing pritelivir in immunocompromised patients with refractory herpes …
-
TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial
A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational new drug (IND) application amendment seeking …
-
Lilly stops development of three drugs, including gene therapy
Eli Lilly is dropping the development of three therapies that did not meet expectations, including a gene therapy acquired during …
-
DiMe unveils sDHT Adoption Navigator to advance clinical trial integration
The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) has introduced the sDHT Adoption Navigator, an …
-
J.P. Morgan Healthcare Conference 2026 Report
The J. P. Morgan Healthcare Conference 2026 (JPM 2026) offers an early view of investor sentiment in the healthcare industry …
-
Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy
Affinia Therapeutics has received approval from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application …
-
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
Ultragenyx Pharmaceutical’s gene therapy has shown durable improvements in patients with Sanfilippo syndrome Type A (MPS IIIA), a rare neurodegenerative …
-
MHRA outlines upcoming IVD submission shift for clinical trials
The Medicines and Healthcare products Regulatory Agency (MHRA) is formalising its review process around in vitro diagnostics (IVD) or companion …
-
NMD Pharma to progress CMT pill despite primary endpoint miss
NMD Pharma is “accelerating development” of its lead rare disease candidate, ignaseclant, in Charcot-Marie-Tooth (CMT), despite the drug failing to …
-
Invivyd aligns with FDA advice on LIBERTY Phase III Covid-19 trial
Invivyd has received advice from the US Food and Drug Administration (FDA) and is aligned with it on the LIBERTY Phase III …
-
Biosion doses first patient in Phase Ia/Ib BSI-082 trial for solid tumours
Biosion has dosed the first patient in an investigator-initiated Phase Ia/Ib trial of BSI-082, a fully human anti-SIRPα monoclonal antibody, …
-
Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Pfizer’s recently acquired weight loss injection has shown to maintain weight loss after a switch from weekly to monthly dosing …
-
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
Novo Nordisk’s CagriSema has outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight …
